Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Over 130,000 US Toddlers and Children Aged 0-5 Are Prescribed Addictive 'Anti-Anxiety' Drugs


News provided by

Citizens Commission on Human Rights International

Oct 17, 2017, 14:08 ET

Share this article

Share toX

Share this article

Share toX

LOS ANGELES, Oct. 17, 2017 /PRNewswire/ -- More than 130,000 children, including 39,000 infants and toddlers, are being prescribed anti-anxiety drugs that are so addictive, the Food and Drug Administration (FDA) warns they should not be prescribed for longer than a few weeks. Mental health watchdog Citizens Commission on Human Rights (CCHR) International obtained the statistics from IMS health, a drug market research firm which also revealed that of this figure, over 98,000 two- to five-year-olds were prescribed the sedative-hypnotic drugs. There has been a nearly 300 percent increase in the drugs prescribed babies and toddlers under the age of two since 2003.[1]

Continue Reading
Over 130,000 U.S. Toddlers and Children Aged 0-5 Are Prescribed Addictive "Anti-Anxiety" Drugs
Over 130,000 U.S. Toddlers and Children Aged 0-5 Are Prescribed Addictive "Anti-Anxiety" Drugs

The class of drugs is called benzodiazepines, also known as "benzos," "sedatives" and "tranquilizers" and has limited approval for the pediatric population for pre-anesthesia. Diazepam has been approved for pediatric use in children with epilepsy. The FDA has also indicated they can be used to treat insomnia and seizures.[2] The drugs are also combined with opioids for operations or for prolonged sedation in intensive care.

According to Psychiatric Drugs in Children and Adolescents Basic Pharmacology and Practical Applications, benzos have "not shown efficacy in anxiety disorders in double-blind placebo-controlled trials in children and adolescents."[3] The Johns Hopkins Psychiatry Guide for benzodiazepines also says that safety of many of them has not been established in children.[4] However, at least one benzo, lorazepam, is FDA-approved for treatment of anxiety in those aged 12 and older.[5] 

None of this explains how nearly 40,000 infants and toddlers can be prescribed such potentially addictive drugs, CCHR says. Indeed, a Psychology Today article in 2009 stated, "It is considered unwise to subject children to the potential for getting caught in the addictive grip of these drugs."

Dr. David Sack, board certified in addiction medicine, says, "Tolerance and dependence can develop quickly. There have been reports of people who received high doses of benzodiazepines becoming physically dependent in as little as two days."[6] 

From Prescription to Addiction

All benzodiazepines are listed as Drug Enforcement Administration (DEA) schedule IV controlled substances because of the potential for abuse, addiction and diversion.[7] 

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), 20 percent of users said they first abused benzodiazepines when they were aged 15 to 17.[8] Between 2007 and 2012, there was a 62.8 percent increase in admittance to a rehabilitation center for benzodiazepine addiction for all age groups.[9] An estimated 10 to 25 percent of longtime users are dependent on them[10] and about 60 percent of people with "benzo" prescriptions experience withdrawals or other adverse side effects from the drugs.[11]

Professor Malcolm Lader of the Institute of Psychiatry, King's College, London, was interviewed for the 2016 documentary, "Benzodiazepine Medical Disaster." He said withdrawing from benzodiazepines is more difficult than getting off heroin.[12]

Professor Heather Ashton, a leading authority on benzodiazepine withdrawal in the United Kingdom, described the range of withdrawal symptoms, including nightmares, increased anxiety, panic attacks, perceptual distortions, depersonalization, hallucinations, paranoid thoughts, rage, aggression, and irritability to name but a few.[13] In an article on protracted withdrawal symptoms, Dr. Ashton also says that in chronic users of the drugs, a "sizeable minority, perhaps 10 to 15 percent develop a 'post-withdrawal syndrome,' which may linger for months or even years." The acute "pharmacological" benzodiazepine withdrawal syndrome is classically described as lasting 5 to 28 days, with a peak in severity around two weeks post-withdrawal, she said.[14]

The FDA also warns that quitting benzodiazepines abruptly can result in more than 40 withdrawal side effects, including headache, anxiety, tension, depression, insomnia, confusion, dizziness, de-realization and short-term memory loss. According to Dr. Harris Stratyner, vice chairman of the National Council on Alcoholism and Drug Dependence and a clinical associate professor of psychiatry at the Mount Sinai School of Medicine in Manhattan, 10 percent of people who quit abruptly may experience a "syndrome" of withdrawal symptoms that extend long after the drugs leave their bodies. This change can reverse, but for a small proportion of people, it can take months or years to recover.[15]

"The two most dangerous drugs to detox off of are benzos and alcohol," said Dr. Stratyner.

Benzos are now among the top-prescribed psychiatric drugs in the United States. Nearly 50 million scripts for the more common types of benzos are written each year. However, according to IMS Health, benzo prescriptions increased from 80 million in 2006 to 94 million in 2013.[16]

Benzos Cause High Overdose Rate

Overdose potential for benzos is high, accounting for thousands of deaths every year in the U.S. The Centers for Disease Control and Prevention (CDC) looked at drug overdose deaths among Americans ages 15 to 19 over a 16-year period, from 1999 to 2015. The CDC's report showed that from 1999 to the mid-2000s, drug overdose deaths in this age group more than doubled, from 1.6 deaths per 100,000 in 1999 to 4.2 deaths per 100,000 in 2007.[17]

Since 2000, there has been a 500 percent increase in the overdose death rate, with about 9,000 benzo-related deaths reported in 2015. Benzos are particularly lethal when combined with opioids, accounting for about 8,000 of these deaths, and around a third of all fatal overdoses involved some form of benzodiazepine.[18]

The Medical Examiners Commission of the Florida Department of Law Enforcement published a report in April 2017 that determined that in the first half of 2016, benzodiazepines caused 632 deaths, including 355 from alprazolam. Alprazolam was common as contributing to the cause of multi-drug deaths.[19]

SAMHSA's latest statistics also reveal an average of 31 people per day aged 12 to 17 went to the emergency room for benzodiazepine abuse.[20]

IMS Health reported an astounding 131,539 children aged six to 10 were taking benzos in 2012; 174,691 were aged 11 to 14 and 255,876 were aged 15 to 18. That's over half a million children and adolescents between the ages of six and eighteen. Adding those aged zero to five, and the U.S. had more than 600,000 infants, children and adolescents taking these drugs in 2012.

By 2015, SAMHSA reported a massive estimated 1.1 million youths aged 12 to 17 (4.3 percent of all youths) had been past year users of tranquilizers, mostly benzodiazepines. [21] Tranquilizer is a broader drug classification that includes major tranquilizers, minor tranquilizers and others, also known as central nervous system depressants.[22]

There are 14 benzodiazepine agents currently available for use in the United States: alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam and triazolam.[23]

Long-acting benzodiazepine agents are associated with accumulation which may result in sedation, cognitive impairment and psychomotor retardation. [24] Other side effects include a "paradoxical excitement and rage" that may occur in so-called hyperactive children.[25] Diazepam may create new or exacerbate existing behavior or mental problems, including hallucinations or sudden suspicions that are more common in children and the elderly.

In 1989, Isaac Marks, Consultant Psychiatrist at South London and Maudsley Hospital trust and former President of the British and European Associations of Behavior Therapy, published in the Archives of General Psychiatry a critique of then-recent reports about alprazolam and its "efficacy" in treating panic disorder (his quotation marks). Marks, with ten other eminent colleagues from comparable research institutes in France, Germany, England, Spain, Portugal, Brazil, and the States, drew yet more attention to "serious adverse effects" of the drug that only "become apparent later," he asserted—long after most clinical trials had wrapped up. He also wrote of worrying signs of brain atrophy [shrinkage] among long-term benzodiazepine users, including "cerebral ventricular enlargement."[26]

The drugs are often combined or prescribed with opioids. Dr. Sack, writing in Psychology Today in June 2017, warned that benzodiazepines are "the danger lurking in the shadow of opiates." Henoted that prescriptions for benzos more than tripled and fatal overdoses more than quadrupled between 1996 and 2013. 

Dr. Sack says both opioids and benzodiazepines slow down body systems, particularly the respiratory and cardiovascular systems. Combining the drugs increases the effects of each exponentially, meaning that the body isn't just processing two doses, it is processing more like three or four. This multi-dose cocktail can cause breathing to stop. [27]

DSM Produces Epidemic in Children Prescribed Benzos

According to a Medpage Today article in February 2014, the prescribing of benzos is also "deeply rooted in another document, the main guide that psychiatrists and other doctors use in diagnosing mental illness—the Diagnostic and Statistical Manual of Mental Disorders." With the 1980 or third edition of the manual, psychiatrists introduced the diagnosis of generalized anxiety disorder. However, there are no medical tests that can confirm the diagnosis for which mind-altering drugs need to be prescribed.

Revisions to the manual, including an update in 2013, expanded that diagnosis, which, in turn, meant more people would be treated, said Allen Frances, MD, the former chair of psychiatry at Duke University. Frances also chaired the DSM panels that developed the fourth (1994) edition of DSM. That edition was mired in controversy as a study found significant financial ties between pharmaceutical companies and panel members who produced the DSM-IV. In the field of anxiety disorders, 81 percent of the panel members had financial connections to drug companies. Frances said that even small changes in the DSM could mean an additional 10 million patients getting psychiatric treatment.[28]

CCHR previously released figures it obtained from IMS Health that over 100,000 children age five or younger were prescribed antidepressants that carry FDA warnings of potentially causing suicidal behavior and suicide. Yet many more in the same age group are on highly addictive benzodiazepines, all of which requires a high priority government investigation and intervention, CCHR says. Insurance companies should also be alert to and report to authorities the high level of and long-term prescription of these drugs to children to help curb the potential for addiction. 

As a nonprofit, CCHR relies on memberships and donations to carry out its mission and actions to curb psychotropic drug use in children and educate parents and families of the risks of psychotropic drugs in its Fight For Kinds campaign. Click here to support the cause. It has already been responsible for helping get over 180 laws enacted, including the 2004 Federal Child Medication Safety Amendment that prohibits schools from forcing children to take psychotropic drugs as a requisite for their education.

Contact: Amber Rauscher, [email protected] or (323) 467-4242.

References:

[1] IMS, Vector One: National (VONA) and Total Patient Tracker (TPT) Database, Years 2008-2013, Extracted 2014.

[2] https://www.fda.gov/Drugs/DrugSafety/ucm518473.htm

[3] https://books.google.com/books?id=AmQlBAAAQBAJ&pg=PA224&lpg=PA224&dq=FDA+approved+benzodiazepines+for+children&source=bl&ots=KgAG1pgVqL&sig=aKAj9u0SYhdJLDn_OSY6hJ88j2Q&hl=en&sa=X&ved=0ahUKEwiPz9K68ObWAhWD0FQKHTHdCxs4ChDoAQhCMAI#v=onepage&q=FDA%20approved%20benzodiazepines%20for%20children&f=false

[4] https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787140/all/Benzodiazepines

[5] Raymond H. White, C. Susan Moseley-Howard (Editors), Mental Health Practice in Today's Schools: Issues and Interventions, (Springer Publishing Co. NY, 2015), https://books.google.com/books?id=UaoiBQAAQBAJ&pg=PA366&lpg=PA366&dq=BENzodiazepines+FDA+approved+in+children+for&source=bl&ots=_6wZJjcn0U&sig=Mk3_VjbECwbOP3GBwl1oDP9YjI4&hl=en&sa=X&ved=0ahUKEwiM7bCNxcnWAhVN7WMKHSX4CtY4ChDoAQgnMAE#v=onepage&q=BENzodiazepines%20FDA%20approved%20in%20children%20for&f=false

[6] David Sack M.D., "Benzodiazepines: The Danger Lurking in the Shadow of Opiates: Fatal overdoses more than quadrupled for benzodiazepines prescriptions," Psychology Today, 29 June 2017, https://www.psychologytoday.com/blog/where-science-meets-the-steps/201706/benzodiazepines-the-danger-lurking-in-the-shadow-opiates

[7] https://www.drugs.com/article/benzodiazepines.html

[8] Kaley Johnson, "From prescription to addiction: Abuse of anxiety medication is on the rise: More Americans are becoming hooked on drugs like (Alprazolam and Diazepam), especially young adults," Missourian, 11 Dec. 2015, https://www.columbiamissourian.com/news/from-prescription-to-addiction-abuse-of-anxiety-medication-is-on/article_bdc750d0-8f06-11e5-98dd-e3045be1f81a.html

[9] Ibid., Kaley Johnson.

[10] We Need to Talk About Our Generation's (Alprazolam) Problem," 23 Aug. 2017,  https://www.vice.com/en_us/article/evvama/we-need-to-talk-about-our-generations-xanax-problem

[11] http://wwlp.com/2017/07/26/benzodiazepine-bill-would-require-labeling-of-side-effects

[12] "Tranquilliser trap: The pain of pill addiction," Irish Examiner, 21 July 2017, http://www.irishexaminer.com/lifestyle/healthandlife/tranquilliser-trap-the-pain-of-pill-addiction-455251.html

[13] Prof. C. Heather Ashton,DM, FRCP,"Benzodiazepines: How They Work and How to Withdraw," Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, 2002,  http://www.benzo.org.uk/manual/bzcha03.htm.

[14] Prof. C. Heather Ashton, "Protracted Withdrawal from Benzodiazepines," Comprehensive Handbook of Drug & Alcohol Addiction, 2004," http://www.benzo.org.uk/pws04.htm

[15] Lauren Cox, "Tranquilizer Detox Withdrawal Can Last Years," ABC News Medical Unit, 1 Dec. 2008, http://abcnews.go.com/Health/DepressionNews/story?id=6354685&page=1

[16] Op cit. David Sack M.D., Psychology Today, https://www.medpagetoday.com/special-reports/specialreports/44479

[17] "Teen Drug Overdose Deaths Increased 19% in 2015," Live Science, 16 Aug. 2017, https://www.livescience.com/60153-teen-drug-overdose-deaths.html

[18] We Need to Talk About Our Generation's (Alprazolam) Problem," 23 Aug. 2017, https://www.vice.com/en_us/article/evvama/we-need-to-talk-about-our-generations-xanax-problem

[19] "Drugs Identified in Deceased Persons by Florida Medical Examiners," The Medical Examiners Commission of the Florida Department of Law Enforcement, April 2017, p. iii

[20]  Op. cit. Kaley Johnson.

[21] https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm

[22] http://www.treatment4addiction.com/drugs/barbiturates/tranquilizers

[23] https://medicaid.utah.gov/pharmacy/ptcommittee/files/Criteria%20Review%20Documents/2016/2016.11%20Benzodiazepines%20in%20Anxiety%20Drug%20Class%20Review.pdf

[24] https://medicaid.utah.gov/pharmacy/ptcommittee/files/Criteria%20Review%20Documents/2016/2016.11%20Benzodiazepines%20in%20Anxiety%20Drug%20Class%20Review.pdf

[25] http://cdn.neiglobal.com/content/pgnp/live/diazepam.pdf

[26] Christopher Lane, Ph.D., "Brain Damage from Benzodiazepines: The Troubling Facts, Risks, and History of Minor Tranquilizers, Researchers have long known that benzodiazepines can cause brain damage," Psychology Today, 18 Nov. 2010, https://www.psychologytoday.com/blog/side-effects/201011/brain-damage-benzodiazepines-the-troubling-facts-risks-and-history-minor

[27] Op. cit, David Sack M.D.

[28] "Killing Pain: Benzo 'Boost' Can Be Deadly," Medpage, 25 Feb., 2014, https://www.medpagetoday.com/special-reports/specialreports/44479

Related Links

Number of Children & Adolescents Taking Psychiatric Drugs in the U.S. 

SOURCE Citizens Commission on Human Rights International

Related Links

http://www.cchrint.org

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.